CHARACTERIZATION OF ANTI-CD137L ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATMENT OF AUTOIMMUNE DISEASES

Master'sMASTER OF SCIENCE (RSH-SOM

Destroy, what destroys you

10.1080/2162402X.2019.1685301OncoImmunology9011-

CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8(+) T cells to Tc1 phenotype

10.1007/s00262-018-2144-xCANCER IMMUNOLOGY IMMUNOTHERAPY676893-90

CD137 negatively affects "browning" of white adipose tissue during cold exposure

10.1074/jbc.AC119.011795JOURNAL OF BIOLOGICAL CHEMISTRY29572034-204

<i>In Vivo</i> Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine

Actively targeted theranostic nanomedicine may be the key for future personalized cancer management. Although numerous types of theranostic nanoparticles have been developed in the past decade for cancer treatment, challenges still exist in the engineering of biocompatible theranostic nanoparticles with highly specific <i>in vivo</i> tumor targeting capabilities. Here, we report the design, synthesis, surface engineering, and <i>in vivo</i> active vasculature targeting of a new category of theranostic nanoparticle for future cancer management. Water-soluble photothermally sensitive copper sulfide nanoparticles were encapsulated in biocompatible mesoporous silica shells, followed by multistep surface engineering to form the final theranostic nanoparticles. Systematic <i>in vitro</i> targeting, an <i>in vivo</i> long-term toxicity study, photothermal ablation evaluation, <i>in vivo</i> vasculature targeted imaging, biodistribution and histology studies were performed to fully explore the potential of as-developed new theranostic nanoparticles

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma (NPC).

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)381

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

10.1007/s00262-021-03075-3CANCER IMMUNOLOGY IMMUNOTHERAPY7161531-154